The contribution of human small intestine to chlorpyrifos biotransformation

Toxicology Letters

Volumn 215, Issue 1, 2012, Pages 42-48

  Leoni, Claudia ^a   Balduzzi, Maria ^b   Buratti, Franca Maria ^a   Testai, Emanuela ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ENEA   (Italy)

Author keywords

Chlorpyrifos; CYP3A4; Human small intestine metabolism; Organophosphorothionate pesticide

Indexed keywords

3,5,6 TRICHLOROPYRIN 2 OL; CHLORPYRIFOS; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; DETOXIFICATION; DUODENUM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; HYDROXYLATION; ILEUM; JEJUNUM; KINETICS; MALE; MICROSOME; PRIORITY JOURNAL; SMALL INTESTINE; WESTERN BLOTTING;

BIOTRANSFORMATION; BLOTTING, WESTERN; CHLORPYRIFOS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DUODENUM; FEMALE; HUMANS; HYDROXYLATION; ILEUM; INSECTICIDES; INTESTINE, SMALL; JEJUNUM; MALE; METABOLIC DETOXICATION, DRUG; MICROSOMES; REGRESSION ANALYSIS; TESTOSTERONE;

EID: 84867604028     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.09.016     Document Type: Article

References (48)

1. Adgate J.L., Barr D.B., Clayton C.A., Eberly L.E., Freeman N.C.G., Lioy P.J., Needham L.L., Pellizzari E.D., Quackenboss J.J., Roy A., Sexton K. Measurement of children's exposure to pesticides: analysis of urinary metabolite levels in a probability-based sample. Environmental Health Perspectives 2001, 109:583-589.
2. Aiba T., Takehara Y., Okuno M., Hashimoto Y. Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharmaceutical Research 2003, 20:745-748.
3. Buratti F.M., Leoni C., Testai E. Foetal and adult human CYP3A isoform in the bioactivation of organophosphorothionate insecticides. Toxicology Letters 2006, 167:245-255.
4. Buratti F.M., Testai E. Malathion detoxification by human hepatic carboxylesterases and its inhibition by isomalathion and other pesticides. Journal of Biochemical and Molecular Toxicology 2005, 19:406-414.
5. Buratti F.M., Volpe M.T., Meneguz A., Vittozzi L., Testai E. CYP-specific bioactivation of four organophosphorothionate pesticides by human liver microsomes. Toxicology and Applied Pharmacology 2003, 186:143-154.
6. Cometa M.F., Buratti F.M., Fortuna S., Lorenzini P., Volpe M.T., Parisi L., Testai E., Meneguz A. Cholinesterase inhibition and alterations of hepatic metabolism by oral acute and repeated chlorpyrifos administration to mice. Toxicology 2007, 234:90-102.
7. Cochran R.C. Appraisal of risks from nonoccupational exposure to chlorpyrifos. Regulatory Toxicology and Pharmacology 2002, 35(1):105-121.
8. Cook T.J., Shenoy S.S. Intestinal permeability of chlorpyrifos using the single-pass intestinal perfusion method in the rat. Toxicology 2003, 184:125-133.
9. Costa L.G., Richter R.J., Li W.-F., Cole T.B., Guizzetti M., Furlong C.E. Paraoxonase (PON1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 2003, 8:1-12.
10. Croom E.L., Wallace A.D., Hogdson E. Human variation in CYP-specific chlorpyrifos metabolism. Toxicology 2010, 276:184-191.
11. Crow J.A., Bittles V., Herring K.L., Borazjani A., Potter P.M., Ross M.K. Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon. Toxicology and Applied Pharmacology 2012, 258:145-150.
12. Eaton D.L., Daroff R.B., Autrup H., Bridges J., Buffler P., Costa L.G., Coyle J., McKhann G., Mobley W.C., Nadel L., Neubert D., Schulte-Hermann R., Spencer P.S. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Critical Reviews in Toxicology 2008, 38(Suppl. 2):1-125.
13. Fagerholm U., Johansson M., Lennemas H. Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical Research 1996, 13:1336-1342.
14. Fenske R.A., Kedan G., Lu C., Fisker-Andersen J.A., Curl C.L. Assessment of organophosphorus pesticide exposure in the diets of preschool children in Washington State. Journal of Exposure Analysis and Environment Epidemiology 2002, 12:21-28.
15. Galetin A., Houston J.B. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. Journal of Pharmacology and Experimental Therapeutics 2006, 318:1220-1229.
16. Griffin P., Mason H., Heywood K., Cocker J. Oral and dermal absorption of chlorpyrifos: a human volunteer study. Journal of Occupational and Environmental Medicine 1999, 56:10-13.
17. Hu Z.Y., Zhao Y.S. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2010, 38(5):817-823.
18. Kivistö K.T., Niemi M., Fromm M.T. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundamental and Clinical Pharmacology 2004, 18:621-626.
19. Komura H., Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. Journal of Pharmaceutical Sciences 2007, 97:1775-1800.
20. Krieger R.I., Chen L., Ginevan M., Watkins D., Cochran R.C., Driver J.H., Ross J.H. Implications of estimates of residential organophosphate exposure from dialkylphosphates (DAPs) and their relevance to risk. Regulatory Toxicology and Pharmacology 2012, 64(2):263-266.
21. Lanning C.L., Fine R.L., Sachs C.W., Rao U.S., Corcoran J.J., Abou-Donia M.B. Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein. Journal of Toxicology and Environment Health 1996, 47:395-407.
22. Leoni C., Buratti F.M., Testai E. The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicology and Applied Pharmacology 2008, 233(2):343-352.
23. Lown K.S., Ghosh M., Watkins P.B. Sequences of intestinal and hepatic cytochrome P450 3A4 of DNAs are identical. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1998, 26:185-187.
24. Matsubara T., Kim H.J., Miyata M., Shimada M., Nagata K., Yamazoe Y. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. Journal of Pharmacology and Experimental Therapeutics 2004, 309:1282-1290.
25. Nolan R.J., Rick D.L., Freshour N.L., Saunders J.H. Chlorpyrifos: pharmacokinetics in human volunteers. Toxicology and Applied Pharmacology 1984, 73:8-15.
26. Obach R.S., Zhang Q.-Y., Dunbar D., Kaminski L.S. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2001, 29:347-352.
27. Paine M.F., Hart H.L., Ludington S.S., Haining R.L., Rettie A.E., Zeldin D.C. The human intestinal cytochrome P450 Pie. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:880-886.
28. Paine M.F., Ludington S.S., Chen M.L., Stewart P.W., Huang S.M., Watkins P.B. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2005, 33:426-433.
29. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins J.D., Thummel K.E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics 1997, 283:1552-1562.
30. Poet T.S., Wu K., Kousba A.A., Timchalk C. In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon. Toxicological Sciences 2003, 72:193-200.
31. Pelkonen O. Biotransformation of xenobiotics in the fetus. Pharmacology & Therapeutics 1980, 10:261-281.
32. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L.O., Vyas K.P. Comparative studies in drug-metabolizing enzymes in dog, monkey and human small intestines, and in Caco-2 cells. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1996, 24:634-642.
33. Rigas M.L., Okino M.S., Quackenboss J.J. Use of pharmacokinetic model to assess chlorpyrifos exposure and dose in children, based on urinary biomarker measurement. Toxicological Sciences 2001, 61:374-381.
34. Rowland-Yeo K., Rostami-Hodjegan A., Tucker G.T. Abundance of cytochromes P450 in human liver: a meta-analysis. British Journal of Clinical Pharmacology 2004, 57:687-688.
35. Sanwald P., Blankson E.A., Dulery B.D., Schoun J., Huebert N.D., Dow J. Isocratic high-performance liquid chromatographic method for the separation of testosterone metabolites. Journal of Chromatography B. Biomedical applications 1995, 672:207-215.
36. Schurdut B.A., Barraj L., Francis M. Aggregate exposures under the food quality protection act: an approach using chlorpyrifos. Regulatory Toxicology and Pharmacology 1998, 28:165-177.
37. Shamir R., Hartman C., Karry R., Pavlotzky E., Eliakim R., Lachter J., Suissa A., Aviram M. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line:molective secretion of PON1 and PON2. Free Radical Biology and Medicine 2005, 39:336-344.
38. Takara K., Ohnishi N., Horibe S., Yokoyama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug ensistance 1 subfamily mRNAs in rat small intestine. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2003, 31:1235-1239.
39. Taketani M., Shii M., Ohura K., Ninomiya S., Imai T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sciences 2007, 81:924-932.
40. Tang J., Cao Y., Rose R.L., Brimfield A.A., Dai D., Goldstein J.A., Hodgson E. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2001, 29:1201-1204.
41. Testai E., Buratti F.M., Di Consiglio E. Chlorpyrifos. Hayes' Handbook of Pesticide Toxicology 2010, 1505-1526. Academic Press Elsevier. 3rd ed. R. Krieger (Ed.).
42. Timchalk C., Nolan R.J., Mendrala A.L., Dittenber D.A., Brzak K.A., Mattsson J.L. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicological Sciences 2002, 66:34-53.
43. Tirelli V., Catone T., Turco L., Di Consiglio E., Testai E., De Angelis I. Effects of the pesticide chlorpyrifos on an in vitro model of intestinal barrier. Toxicology in Vitro 2007, 21:308-313.
44. Turco L., Catone T., Caloni F., Di Consiglio E., Testai E., Stammati A. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human?. Toxicology in Vitro 2011, 25:13-20.
45. von Richter O., Burk O., Fromm M.F., Thon K.P., Eichelbaum M., Kivistö K.T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clinical Pharmacology and Therapeutics 2004, 75:172-183.
46. Yang J., Tucker G.T., Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clinical Pharmacology and Therapeutics 2004, 76:391.
47. Zhang Q.-Y., Dunbar D., Ostrowska A., Zeisloft S., Yang J., Kaminski L.S. Characterization of human small intestinal cytochromes P-450. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1999, 27:804-809.
48. Zhang Y., Benet L.Z. The gut as a barrier to drug absorption combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics 2001, 40:159-168.